

Understanding and managing fevers from infections spread by animals

Submission date 13/06/2024	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 27/06/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 17/06/2024	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Acute fevers are a major health problem in sub-Saharan Africa, where they cause nearly 40% of children's deaths. When children have a fever, they are often assumed to have malaria or a bacterial infection and are treated for these conditions. This may lead to wrong treatment, causing preventable deaths, and unnecessary use of antibiotics, which adds to the problem of rising antimicrobial resistance. Many of these fevers might actually be caused by diseases passed from animals to people, known as zoonotic infections. These diseases are not studied as much as other causes of fever, and diagnosing them is tough because doctors do not have much training in them and testing is limited in Africa. This study aims to understand how common these zoonotic infections are and to find better ways to diagnose and manage the fevers they cause.

Who can participate?

Children aged 2 months to under 18 years, of both sexes, who come to participating health facilities with an acute fever.

What does the study involve?

The children will have a series of health checks and tests. The researchers will take a small amount of blood and urine to test for different infections that might be causing their fever. They will use both well-established and cutting-edge tests to see if they can enhance how they diagnose these illnesses. The researchers will also talk with the children and their caregivers about their symptoms, recent animal contacts, and other potential sources of infection they have been exposed to.

What are the possible benefits and risks of participating?

Children participating in this study may benefit from extra tests that could identify a treatable infection that might otherwise go undiagnosed. By joining this study, they will also help increase our understanding of how often these zoonotic infections occur, which could improve how doctors treat similar cases in the future. There may be some minor risks, such as short-term pain, bruising, or infection where the blood is taken, but there are no other significant risks involved in participating in the study.

Where is the study run from?

This study is a collaboration among researchers from:

1. University of Liverpool (lead) and Liverpool School of Tropical Medicine (UK)
2. Kabale University (joint lead) and Makerere University (Uganda)
3. University of Nairobi and International Livestock Research Institute (ILRI) (Kenya)
4. Addis Ababa University and ILRI (Ethiopia)

When is the study starting and how long is it expected to run for?

November 2022 to June 2028

Who is funding the study?

National Institute for Health and Care Research (UK)

Who is the main contact?

Dr Siobhan Mor, siobhan.mor@liverpool.ac.uk

Contact information

Type(s)

Public, Scientific, Principal Investigator

Contact name

Dr Siobhan Mor

ORCID ID

<http://orcid.org/0000-0003-0121-2016>

Contact details

Institute of Infection, Veterinary and Ecological Sciences

University of Liverpool

Leahurst Campus

Neston

United Kingdom

CH64 7TE

+251 (0)940793351

siobhan.mor@liverpool.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

NIHR156365

Study information

Scientific Title

NIHR Global Health Research Group on zoonotic causes of acute febrile illness

Acronym

ZAFI

Study objectives

Acute fevers are a leading cause of child deaths in sub-Saharan Africa. Many of these fevers are due to diseases spread from animals to humans, known as 'zoonoses'. Diagnosing these infections is often overlooked in low-resource areas, leading to poor awareness and delayed treatment. Improving the recognition and diagnosis of zoonoses can enhance early detection and treatment, ultimately saving lives and reducing illness from these infections.

Ethics approval required

Ethics approval required

Ethics approval(s)

Not yet submitted

Study design

Multicenter facility-based cross-sectional study

Primary study design

Observational

Secondary study design

Cross sectional study

Study setting(s)

Hospital, Laboratory

Study type(s)

Diagnostic, Other

Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Zoonotic causes of acute febrile illness in children

Interventions

Following consent/assent, a detailed questionnaire on symptoms/signs, socio-economic status, dietary preferences/practices and other household exposures (human, animal, environment) will be completed by the study nurse. All enrolled patients will receive a malaria rapid diagnostic test (RDT). Patients with a positive test will generally exit the study at this stage and will be treated with antimalarials according to clinical guidelines at each facility.

Subsequently, blood (5 ml by venepuncture) and voided urine will be collected and submitted for bacterial culture and Gram staining. Markers of inflammation (white blood cell counts and c-reactive protein) will be assessed in all patients. In patients with positive blood culture, suspect *Salmonella* colonies will be subjected to multiplex PCR to detect *S. typhi* (typhoid) and pan-*Salmonellae*.

In patients with a negative culture, blood will be further subjected to comprehensive pathogen testing using reference standard diagnostics, qPCR and novel diagnostic platforms for bacterial zoonotic pathogens (*Brucella*, *Leptospira*, *Coxiella*, *Rickettsia* spp.) and arboviral infections (Crimean-Congo Hemorrhagic Fever [CCHF], Rift Valley Fever [RVF], Dengue Virus [DENV], Chikungunya Virus [CHIKV], Zika Virus [ZIKV], West Nile Virus [WNV], Yellow Fever [YF]). PCR fragments from confirmed *Leptospira* cases will also be subjected to serotyping. Patients that receive a positive diagnosis for a bacterial infection will be treated with appropriate antibiotics and all patients will receive supportive treatment as indicated according to clinical guidelines at each facility.

Intervention Type

Other

Primary outcome measure

The presence of one or more bacterial zoonotic pathogens or arboviruses measured using reference standard diagnostics, qPCR and novel diagnostic platforms at presentation to the health centre

Secondary outcome measures

1. Clinical characteristics measured using clinical history, physical examination and laboratory testing at presentation to the health centre
2. Socio-economic status, dietary preferences/practices and other household exposures measured using questionnaire designed for the study at presentation to the health centre
3. Diagnostic accuracy, time to result, and potential impact on treatment measured using clinical and laboratory records after application of novel diagnostic platforms

Overall study start date

23/11/2022

Completion date

30/06/2028

Eligibility

Key inclusion criteria

1. Male and female children aged ≥ 2 months and < 18 years
2. Presents to healthcare facility with a history of fever in the past 48 h, OR an axillary temperature $> 37.5^{\circ}\text{C}$, OR a rectal temperature of $\geq 38.0^{\circ}\text{C}$
3. Caregiver provides full and free informed consent
4. Children aged 8-17 years provide full and free assent

Participant type(s)

Patient

Age group

Child

Lower age limit

2 Months

Upper age limit

17 Years

Sex

Both

Target number of participants

4000

Key exclusion criteria

1. Unknown age
2. Known malignancy, renal failure, hepatic failure, bone marrow aplasia
3. Trauma, surgery

Date of first enrolment

01/07/2025

Date of final enrolment

30/09/2027

Locations

Countries of recruitment

Ethiopia

Kenya

Uganda

Study participating centre

Kabale Regional Referral Hospital

Kabale

Uganda

-

Study participating centre

Mulago National Referral Hospital

Kampala

Uganda

-

Study participating centre
Mbagathi County Hospital
Nairobi
Kenya

-

Study participating centre
Loitoktok Sub-County Hospital
Oloitoktok
Kenya

-

Study participating centre
Ziway Health Centre
Ziway
Ethiopia

-

Study participating centre
Butajira General Hospital
Butajira
Ethiopia

-

Sponsor information

Organisation
University of Liverpool

Sponsor details
Brownlow Hill
Liverpool
England
United Kingdom
L69 3BX
+44 (0)7717 863747
sponsor@liverpool.ac.uk

Sponsor type
University/education

Website

<http://www.liv.ac.uk/>

ROR

<https://ror.org/04xs57h96>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health and Care Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

The research will be disseminated to the public through the use of community conversations and social media, with a focus on our emerging data regarding causative agents of fever, risk factors for infection, and how they are treated, diagnosed and prevented.

The researchers will influence policymakers and clinicians through panel discussions and policy briefs. A key objective is to generate improved tools for the diagnosis and management of zoonotic causes of acute febrile illness and then to integrate these into national policy via the national Ministry of Health in each country.

Academic audiences will be reached through scientific journals, regular website updates, and presentations at local and international conferences.

Intention to publish date

30/06/2029

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date